Patents by Inventor Glenn Pierce

Glenn Pierce has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FACTOR IX POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20190192640
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: February 8, 2019
    Publication date: June 27, 2019
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • FACTOR IX POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20190192641
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: February 8, 2019
    Publication date: June 27, 2019
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
    Patent number: 10221455
    Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
    Type: Grant
    Filed: January 12, 2013
    Date of Patent: March 5, 2019
    Assignees: BIOVERATIV THERAPEUTICS INC., PUGET SOUND BLOOD CENTER
    Inventors: Haiyan Jiang, Tongyao Liu, Sriram Krishnamoorthy, Neil Josephson, Glenn Pierce
  • FACTOR VIII CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF
    Publication number: 20180360982
    Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 20, 2018
    Applicant: Bioverativ Therapeutics Inc.
    Inventors: Jennifer A. DUMONT, Susan LOW, Alan J. BITONTI, Glenn PIERCE, Alvin LUK, Haiyan JIANG, Byron MCKINNEY, Matt OTTMER, Jurg SOMMER, Karen NUGENT, Lian LI, Robert T. PETERS
  • Factor IX Polypeptides and Methods of Use Thereof
    Publication number: 20180228879
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: February 6, 2018
    Publication date: August 16, 2018
    Applicant: Bioverativ Therapeutics Inc.
    Inventors: Glenn PIERCE, SAMANTHA TRUEX, ROBERT T. PETERS, HAIYAN JIANG
  • Factor IX Polypeptides and Methods of Use Thereof
    Publication number: 20180228878
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: February 6, 2018
    Publication date: August 16, 2018
    Applicant: Bioverativ Therapeutics Inc.
    Inventors: GLENN PIERCE, SAMANTHA TRUEX, ROBERT T. PETERS, HAIYAN JIANG
  • Targeted coagulation factors and method of using the same
    Patent number: 10035840
    Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: July 31, 2018
    Assignee: Bayer HealthCare LLC
    Inventors: Richard Feldman, Ji-Yun Kim, Haiyan Jiang, Kirk McLean, Junliang Pan, Glenn Pierce, James Wu, Xiao-Yan Zhao
  • Factor IX Polypeptides and Methods of Use Thereof
    Publication number: 20180207244
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: November 21, 2017
    Publication date: July 26, 2018
    Inventors: Glenn PIERCE, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
    Patent number: 10010622
    Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: July 3, 2018
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitoni, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • Factor IX polypeptides and methods of use thereof
    Patent number: 9867873
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: January 16, 2018
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Methods of Using FIX Polypeptides
    Publication number: 20180002684
    Abstract: The present invention provides methods of administering long-acting Factor IX; methods of administering long-acting, chimeric and hybrid polypeptides comprising Factor IX; and methods of producing such chimeric and hybrid polypeptides using cells.
    Type: Application
    Filed: June 9, 2017
    Publication date: January 4, 2018
    Applicant: Bioverativ Therapeutics Inc.
    Inventors: Glenn PIERCE, Samantha TRUEX, Robert T. PETERS, Haiyan JIANG
  • Factor IX polypeptides and methods of use thereof
    Patent number: 9675676
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: June 13, 2017
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Factor IX polypeptides and methods of use thereof
    Patent number: 9670475
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: June 6, 2017
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Factor IX polypeptides and methods of use thereof
    Patent number: 9629903
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: April 25, 2017
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Factor IX polypeptides and methods of use thereof
    Patent number: 9623091
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: April 18, 2017
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • TARGETED COAGULATION FACTORS AND METHOD OF USING THE SAME
    Publication number: 20170051042
    Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.
    Type: Application
    Filed: July 28, 2016
    Publication date: February 23, 2017
    Inventors: Richard FELDMAN, Ji-Yun KIM, Haiyan JIANG, Kirk MCLEAN, Junliang PAN, Glenn PIERCE, James WU, Xiao-Yan ZHAO
  • Factor IX Polypeptides and Methods of Use Thereof
    Publication number: 20160346365
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: February 12, 2016
    Publication date: December 1, 2016
    Applicant: Biogen Hemophilia Inc.
    Inventors: Glenn PIERCE, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Factor IX Polypeptides and Methods of Use Thereof
    Publication number: 20160257943
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: December 29, 2015
    Publication date: September 8, 2016
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Factor IX Polypeptides and Methods of Use Thereof
    Publication number: 20160243206
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: February 12, 2016
    Publication date: August 25, 2016
    Applicant: Biogen Hemophilia Inc.
    Inventors: Glenn PIERCE, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Targeted coagulation factors and method of using the same
    Patent number: 9422362
    Abstract: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: August 23, 2016
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Richard Feldman, Ji-Yun Kim, Haiyan Jiang, Kirk Mclean, Junliang Pan, Glenn Pierce, James Wu, Xiao-Yan Zhao